Diagnostics

A perfect storm of economic shifts and private equity pressure is set to ignite the dental M&A market, creating huge opportunities for practice owners.

Sanuwave Health posts record revenue, defying industry-wide turmoil as reimbursement cuts reshape the advanced wound care market. How did they do it?

Swiss lab automation giant Tecan shows signs of a turnaround with robust H2 2025 orders, betting on AI to navigate a recovering life sciences market.

With a new CEO from Illumina and Exact Sciences, Quanterix signals a strategic shift from tech development to aggressive market and clinical expansion.

From firefighting robots to AI health diagnostics, Hong Kong's record delegation at CES 2026 wins big, signaling its arrival as a global tech powerhouse.

As ENvue Medical prepares to ring the Nasdaq bell, a look at how its non-invasive tech for tube placement and pain relief is shaking up the MedTech world.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

The diagnostics firm's new offering combines sample collection with CRO and CDMO services, aiming to slash timelines and reduce regulatory risk for developers.

A breakthrough liquid biopsy shows over 80% accuracy in finding feline lymphoma, offering a non-invasive screening tool for vets and hope for cat owners.

The biotech firm launches an early access program for its novel platform, starting with a tau assay that could revolutionize Alzheimer's research.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

A new partnership brings revolutionary 3D genome mapping from the lab to the clinic, offering new hope for patients with hard-to-treat cancers.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

AI data platform Protege raises its Series A to $65M, tackling the critical data bottleneck with an ethical, licensing-first model for real-world data.

A newly validated genetic test accurately predicts melanoma risk, offering a non-invasive alternative to the standard surgical biopsy for many patients.

After success in Europe, Allotex gets FDA nod to begin U.S. trials for its tissue-based presbyopia treatment, offering new hope for millions.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Dr. Jesse Ehrenfeld's jump to Aidoc validates enterprise AI's role in medicine, as the tech giant surpasses 100 million patient scans analyzed.